Analyst Price Targets — RAPP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:16 am | Tiago Fauth | Raymond James | $75.00 | $47.42 | StreetInsider | Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James |
| August 12, 2026 4:27 pm | Douglas Tsao | H.C. Wainwright | $66.00 | $47.42 | TheFly | Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright |
| June 24, 2026 10:32 am | — | Leerink Partners | $52.00 | $38.88 | TheFly | Rapport Therapeutics initiated with an Outperform at Leerink |
| May 21, 2026 11:46 am | — | BTIG | $65.00 | $35.72 | TheFly | Rapport Therapeutics price target raised to $65 from $53 at BTIG |
| May 18, 2026 10:56 pm | — | Truist Financial | $56.00 | $35.18 | TheFly | Rapport Therapeutics assumed with a Buy at Truist |
| April 10, 2026 9:40 am | Tiago Fauth | Raymond James | $66.00 | $34.12 | TheFly | Rapport Therapeutics initiated with a Strong Buy at Raymond James |
| March 9, 2026 1:49 pm | Kambiz Yazdi | BTIG | $47.00 | $29.97 | StreetInsider | BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough" |
| February 2, 2026 10:58 am | Benjamin Burnett | Wells Fargo | $43.00 | $26.61 | TheFly | Rapport Therapeutics initiated with an Overweight at Wells Fargo |
| December 19, 2025 10:19 am | — | Wells Fargo | $51.00 | $29.64 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Rapport Therapeutics (RAPP) |
| December 9, 2025 11:09 am | Douglas Tsao | H.C. Wainwright | $40.00 | $30.16 | TheFly | Rapport Therapeutics price target raised to $40 from $34 at H.C. Wainwright |
Latest News for RAPP
BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global…
Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 32,212 shares of the company's stock, valued at approximately $1,342,000. Deutsche Bank AG owned about
Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 223,822 shares of the company's stock, valued at approximately $9,327,000. Algert Global LLC owned about 0.47% of Rapport Therapeutics
Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.34 and last traded at $49.33, with a volume of 365422 shares changing hands. The stock had previously closed at $48.24. Analyst Upgrades and Downgrades A number of research
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RAPP.
U.S. House Trading
No House trades found for RAPP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.